COVID-19 Testing for the Essential Workforce

Learn about our efforts to test people on the front line and how you can help.

MiraKind Responds to the COVID-19 Pandemic

Home  /  Community  /  Blog  /  Genetic Research  /  MiraKind Responds to the COVID-19 Pandemic

MiraKind Responds to the COVID-19 Pandemic

At MiraKind, we believe knowledge is power. That belief has never held truer than today, as we face a global pandemic that can only be stamped out with knowledge–knowledge of who is infected so that we can prevent further spread of COVID-19.

In response to the COVID-19 pandemic, MiraKind is using charitable donations to provide COVID-19 tests free of charge to healthcare professionals and first responders who are on the front lines of this pandemic.

MiraKind is the non-profit partner of MiraDx, a molecular diagnostic company founded in 2009 to advance the field of personalized genetic medicine. When news of the pandemic began to emerge, MiraDx’s co-founder and MiraKind’s founder, Joanne Weidhaas, recognized an opportunity to address one of the biggest issues in the COVID crisis today: a significant nationwide testing shortage. Joanne and her team quickly mobilized to transition MiraDx’s CLIA-certified laboratory over to provide COVID testing, leveraging much of the same equipment and protocols they use for their cancer research.

At MiraKind, we are committed to helping individuals get access to important information about their own health so that they can make informed decisions. In that spirit, we set out to help address the urgent goal of helping individuals–particularly the health care professionals and first responders who are the frontlines every day–get access to testing to ensure they can best serve their patients and communities while preventing further spread of the disease.

The COVID-19 pandemic has overwhelmed us all, but we have the opportunity to change the trajectory, starting now.

To learn more about MiraKind’s COVID-19 response and how you might help, go to 330milliontests.org.

STAY INFORMED /

SHARE

Reader Interactions

Leave a Reply

Your email address will not be published. Required fields are marked *